Professor James Leahy has extensive experience in researching to discover new drug candidates with fully optimized pharmacokinetic and pharmacodynamics parameters, having advanced more than a dozen compounds into human clinical trials including the discovery of Cometriq/Cabozantinib/XL184. Toward this end, the Leahy group is actively engaged in collaborative research efforts aimed at the synthesis and optimization of small molecule leads in a number of therapeutic areas such as infectious diseases and neurological disorders as well as the pursuit of novel synthetic methodology.

Experience

  • –present
    Professor of Chemistry; Interim Chair of the Chemistry Department, University of South Florida

Contact James for

  • General
  • Media request
  • Speaking request
  • Consulting / Advising
  • Research collaboration
  • Research supervision